Udo Peters
About Udo Peters
Udo Peters is a Pharmareferent at Bristol-Myers Squibb with over 30 years of experience. He holds a degree in Tax Law/Accounting and a Diploma in Business Administration from Hochschule Bremen.
Current Role at Bristol-Myers Squibb
Udo Peters currently holds the position of Pharmareferent at Bristol-Myers Squibb. He has been with the company for an extensive period, beginning his tenure in April 1991. In his role as a Pharmareferent, Udo Peters specializes in the promotion and detailing of pharmaceutical products to healthcare professionals. His work involves a thorough understanding of product information, clinical trial data, and adherence to strict regulatory guidelines. Udo’s long-term commitment to Bristol-Myers Squibb reflects his expertise and dedication in the pharmaceutical sector.
Educational Background
Udo Peters pursued higher education at Hochschule Bremen, where he studied Steuerrecht/Rechnungswesen, which translates to Tax Law and Accounting. He dedicated five years to his studies, from 1984 to 1989, culminating in the achievement of the title Dipl. Betriebswirt. This diploma in Business Administration provided him with a strong foundation in financial and legal aspects of business management, which has supported his career in the pharmaceutical industry.
Professional Tenure
Udo Peters has amassed over 30 years of experience with Bristol-Myers Squibb. Starting in April 1991, his extensive tenure has allowed him to gain deep insights into the company's operations and the pharmaceutical industry as a whole. His long-term service is indicative of his reliability and professional integrity, contributing significantly to his role in the promotion of pharmaceutical products.
Degree in Tax Law and Accounting
Udo Peters holds a degree in Steuerrecht/Rechnungswesen (Tax Law/Accounting) from Hochschule Bremen. This field of study provided him with an in-depth understanding of complex tax regulations and accounting principles. The knowledge gained from this degree has been instrumental in his approach to the business aspects of the pharmaceutical industry.